$GLUE

Manning Anthony M. sold $231K of GLUE

Manning Anthony M. sold 10,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.11 ($0.23M total) on 2026-06-29.

Original reporting
SEC EDGAR · Manning Anthony M.
Published Jun 30, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GLUE
Neutral
low confidence
Mentioned
$GLUE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

A director’s open-market sale of 10,000 shares at $23.11 is new information, but it does not include any accompanying company-specific news (earnings, trial results, guidance, or regulatory action).

02

Market read

Traders may monitor for follow-on insider activity or confirm whether the sale aligns with broader ownership trends, but the text alone is unlikely to drive a major repricing.

03

What to watch

The filing does not disclose motivations, tax events, or whether other insiders/large holders are changing positions; traders should avoid over-weighting a single sale.

Relevance 4/10Novelty 5/10Timing: after-hours/filing date (2026-06-30) for a 2026-06-29 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralLow confidence
Context

SEC Form 4 shows director Manning Anthony sold 10,000 shares of Monte Rosa Therapeutics at $23.11 on 2026-06-29, leaving 0 shares.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other news.

Evidence & confidence

This is a routine Form 4 transaction with no 10b5-1 plan stated and no accompanying operational/regulatory update in the text.

Market effects

No sector read-through provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for diversification or liquidity needs; without a stated 10b5-1 plan, the sale still may not signal negative fundamentals.

Key entities

  • Monte Rosa Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director sold 10,000 shares at $23.11.

  • Manning Anthony M.

    Director who executed the open-market sale disclosed on Form 4.

Related articles

$GLUEMed

Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029

Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.

$GLUEMed

Monte Rosa Therapeutics, Inc. (GLUE): Results of Operations and Financial Condition

Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout

$GLUEMed

Why is Monte Rosa Therapeutics stock plunging today?

Amazon shares rally as cloud growth surges and spending outlook climbs Investing.com -- Monte Rosa Therapeutics shares plummeted nearly 29.9% in pre-open trading today, trading at $15.90, after Novo Nordisk disclosed that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab — an IL-6 pathway inhibitor — failed to demonstrate a statistically meaningful reduction in major adverse cardiovascular events versus placebo in patients with atherosclerotic cardiovascular disease, chronic...

$GLUEMedAI 9/10

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy

Monte Rosa Therapeutics (GLUE) reported May 7 progress in its clinical pipeline, with three programs moving toward Phase 2. MRT-8102 (NEK7) showed CRP reductions in early trials and plans multiple Phase 2 starts in H2 2026. MRT-6160 (VAV1) with Novartis and MRT-2359 (GSPT1) in mCRPC also advance, with a Phase 2 combo with apalutamide planned for Q3 2026. The company reported $671M cash, expected to fund operations into 2029.

$GLUEMedAI 9/10

Molecule glue drugs shake up cancer care, draw big money

Revolution Medicines (RevMed) said its daraxonrasib doubled survival in aggressive pancreatic cancer, from 6.7 to 13.2 months, with final-stage results due at a Chicago medical conference. The outcome has spurred dealmaking and development of “molecular glue” drugs targeting “undruggable” proteins. RevMed’s market cap neared $33B; it plans FDA filing and an ultrafast review, with projected $7B annual sales by 2032.